<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Describe how <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> are prescribed in France in 2009 and 2010 and assess the effect of the presence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> on the characteristics of the treatment </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The French League Against <z:hpo ids='HP_0000822'>Hypertension</z:hpo> Surveys (FLAHS) are conducted among a representative sample of individuals aged 35 years and older living in France </plain></SENT>
<SENT sid="2" pm="."><plain>For the 2009 and 2010 surveys, a sample of 2292 subjects who declared to take one or more <z:chebi fb="0" ids="35674">antihypertensive drug</z:chebi> has been studied </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to the details of <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medications taken the day of the survey, the personal history for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> was compiled </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the 2292 prescriptions with at least one <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> prescription frequencies are: ARB (43%), <z:chebi fb="40" ids="35498">diuretics</z:chebi> (43%), beta-blockers (34%), CCB (26%), ACEI (26%), <z:chebi fb="0" ids="9241">spironolactone</z:chebi> (8%), central and alpha (7%), DRI (1%) </plain></SENT>
<SENT sid="5" pm="."><plain>The prescription is performed as monotherapy (42%), bitherapy (37%), triple therapy (16%) and quadruple or more (5%) </plain></SENT>
<SENT sid="6" pm="."><plain>When triple therapy is prescribed, there is an association ACEI or ARB or DRI+Diu+BB in 46%, and an association ACEI or ARB or DRI+Diu+AC in 30% </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> is present or past reported by 24% of hypertensive patients: <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (13%), <z:hpo ids='HP_0001635'>heart failure</z:hpo> (6%), <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (5%), <z:hpo ids='HP_0001297'>stroke</z:hpo> (4%), PAD (4%) </plain></SENT>
<SENT sid="8" pm="."><plain>The use of BB is more common in hypertensive patients who have <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> are more common in hypertensive patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo> or <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CCB are more frequent in cases of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> or PAD </plain></SENT>
<SENT sid="11" pm="."><plain>The ARB are less frequent in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The ARB, <z:chebi fb="40" ids="35498">diuretics</z:chebi> and beta-blockers are the most prescribed <z:chebi fb="0" ids="35674">antihypertensives</z:chebi> in France in 2009 to 2010 </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular diseases</z:e> declared in 24% of hypertensives led to a preferential prescription of an <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> or BB </plain></SENT>
</text></document>